We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Optimal Therapy for ICD Patients

By HospiMedica staff writers
Posted on 31 Jan 2006
A new clinical study compared different pharmacologic therapies in patients with implantable cardioverter defibrillators (ICDs), and recommended that those patients use amiodarone plus a beta blocker.

The study, dubbed OPTIC (Optimal Pharmacological Therapy in Implantable Cardioverter Defibrillator Patients), was sponsored by St. More...
Jude Medical (St. Paul, MN, USA) and shows that patients with an ICD reduced their chances of receiving any shock to 10.3% per year when taking the drug amiodarone combined with a beta blocker. This was in contrast to a chance of 24.3% for patients on the drug sotalol alone, and 38.5% for patients on a beta blocker alone. In addition, the amiodarone and beta blocker medical regimen reduced the chance of a patient having an inappropriate shock to only 3.3% per year.

The researchers concluded that amiodarone plus a beta blocker significantly reduced appropriate, inappropriate, and total number of shocks by suppressing ventricular tachycardia, sinus tachycardia and supraventricular arrhythmias. The results were published in the January 11, 2006, edition of The Journal of the American Medical Association.

"What the OPTIC Study makes clear is that, despite the ability of ICDs with advanced dual-chamber discrimination algorithms to reduce the occurrence of inappropriate therapies, the use of antiarrhythmic drugs can significantly reduce ICD shocks,” said Stuart J. Connolly, M.D., principal investigator of the OPTIC study and director of cardiology at McMaster University in Hamilton (Ontario, Canada).





Related Links:
St. Jude Medical
McMaster University

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.